COSCIENS Selling General Administrative vs Long Term Debt Analysis
| CSCI Stock | 2.91 0.00 0.00% |
COSCIENS Biopharma financial indicator trend analysis is way more than just evaluating COSCIENS Biopharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether COSCIENS Biopharma is a good investment. Please check the relationship between COSCIENS Biopharma Selling General Administrative and its Long Term Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in COSCIENS Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.
Selling General Administrative vs Long Term Debt
Selling General Administrative vs Long Term Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of COSCIENS Biopharma Selling General Administrative account and Long Term Debt. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between COSCIENS Biopharma's Selling General Administrative and Long Term Debt is -0.69. Overlapping area represents the amount of variation of Selling General Administrative that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of COSCIENS Biopharma, assuming nothing else is changed. The correlation between historical values of COSCIENS Biopharma's Selling General Administrative and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Selling General Administrative of COSCIENS Biopharma are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Selling General Administrative i.e., COSCIENS Biopharma's Selling General Administrative and Long Term Debt go up and down completely randomly.
Correlation Coefficient | -0.69 |
| Relationship Direction | Negative |
| Relationship Strength | Weak |
Selling General Administrative
Long Term Debt
Long-term debt is a debt that COSCIENS Biopharma has held for over one year. Long-term debt appears on COSCIENS Biopharma balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on COSCIENS Biopharma balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.Most indicators from COSCIENS Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into COSCIENS Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in COSCIENS Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.The COSCIENS Biopharma's current Tax Provision is estimated to increase to about (855.6 K). The current Selling General Administrative is estimated to decrease to about 3.7 M
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 8.2M | 8.1M | 3.0M | 5.1M | Total Revenue | 13.5M | 13.9M | 7.3M | 9.3M |
COSCIENS Biopharma fundamental ratios Correlations
Click cells to compare fundamentals
COSCIENS Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Currently Active Assets on Macroaxis
When determining whether COSCIENS Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of COSCIENS Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cosciens Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cosciens Biopharma Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in COSCIENS Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of COSCIENS Biopharma. If investors know COSCIENS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about COSCIENS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.69) | Revenue Per Share 3.759 | Quarterly Revenue Growth 0.041 | Return On Assets (0.23) | Return On Equity (0.66) |
The market value of COSCIENS Biopharma is measured differently than its book value, which is the value of COSCIENS that is recorded on the company's balance sheet. Investors also form their own opinion of COSCIENS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is COSCIENS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because COSCIENS Biopharma's market value can be influenced by many factors that don't directly affect COSCIENS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between COSCIENS Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if COSCIENS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, COSCIENS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.